Somewhat Positive News Coverage Somewhat Unlikely to Impact Cryolife (CRY) Stock Price

Press coverage about Cryolife (NYSE:CRY) has been trending somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cryolife earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 46.6774065777519 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Cryolife (NYSE:CRY) traded up $0.65 during mid-day trading on Friday, reaching $17.50. The company had a trading volume of 97,655 shares, compared to its average volume of 86,220. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. Cryolife has a 12 month low of $14.02 and a 12 month high of $24.00. The firm has a market cap of $585.52, a PE ratio of 62.50 and a beta of 0.77.

Several research firms recently issued reports on CRY. Zacks Investment Research cut Cryolife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price objective on shares of Cryolife in a report on Wednesday, January 3rd. Northland Securities reiterated a “buy” rating and issued a $23.50 price objective on shares of Cryolife in a report on Monday, November 13th. Finally, TheStreet cut Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $23.63.

In other news, VP David C. Gale sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $19.63, for a total transaction of $392,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 6.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Cryolife (CRY) Stock Price” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2018/02/11/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-cryolife-cry-stock-price.html.

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply